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SUMMARY. The present study was performed to compare the bioavailability of two digoxin 0.25 mg tablet
formulation in 30 volunteers of both sexes. The study was conducted open with randomized two period
crossover design and a three-week washout period. Plasma samples were obtained over a 144 h interval.
Digoxin concentrations were analyzed by a validated microparticle enzyme immunoassay with optical de-
tection by fluorescence. Bioequivalence between the products was determined by calculating 90 % confi-
dence intervals (90 % I.C) for the ratio of AUC0-72h and Cmax values for the test and reference products,
using logarithmic transformed data. The 90 % confidence intervals were 86.98–118.33 %, and 84.52–98.76
%, respectively. Since the 90 % confidence intervals for Cmax and AUC0-72h were within the 80–125 % in-
terval proposed by Food and Drug Administration, it was concluded that the two Digoxin formulations are
bioequivalent in their rate and extent of absorption. 
